NANOG is a stem cell transcription factor that is essential for embryonic development, reprogramming normal adult cells and malignant transformation and progression. The nearly identical retrogene NANOGP8 is expressed in multiple cancers, but generally not in normal tissues and its function is not well defined. Our postulate is that NANOGP8 directly modulates the stemness of individual human colorectal carcinoma (CRC) cells. Stemness was measured in vitro as the spherogenicity of single CRC cells in serum-free medium and the size of the side population (SP) and in vivo as tumorigenicity and experimental metastatic potential in NOD/SCID mice. We found that 80% of clinical liver metastases express a NANOG with 75% of the positive metastases containing NANOGP8 transcripts. In all, 3-62% of single cells within six CRC lines form spheroids in serum-free medium in suspension. NANOGP8 is translated into protein. The relative expression of a NANOG gene increased 8-to 122-fold during spheroid formation, more than the increase in OCT4 or SOX2 transcripts with NANOGP8 the more prevalent family member. Short hairpin RNA (shRNA) to NANOG not only inhibits spherogenicity but also reduces expression of OCT4 and SOX2, the size of the SP and tumor growth in vivo. Inhibition of NANOG gene expression is associated with inhibition of proliferation and decreased phosphorylation of G2-related cell-cycle proteins. Overexpression of NANOGP8 rescues single-cell spherogenicity when NANOG gene expression is inhibited and increases the SP in CRC. Thus, NANOGP8 can substitute for NANOG in directly promoting stemness in CRC.
INTRODUCTION
Normal and malignant adult cells retain the capacity to be reprogrammed to induced pluripotent stem cells from mouse and human adult cells, [1] [2] [3] from patients 4 and from cancer cells. 5 The core embryonic stem (ES) cell transcription factors (TFs) OCT4, SOX2 and NANOG are central to such reprogramming although other genes like KLF4, c-Myc, Lin28 [1] [2] [3] are also involved. NANOG is essential for stemness in adult cells 6 and during embryonic development, 7, 8 while OCT4 and SOX2 are dispensable for reprogramming induced pluripotent stem cells. 9, 10 NANOG is a homeobox protein that is regulated at the allelic level to maintain the pluripotent ground state. 11 NANOG has a retrogene NANOGP8 that appears to be the prevalent NANOG expressed in human breast cancer, 12 prostate cancer, 13, 14 medulloblastoma and glioblastoma multiforme, 15, 16 colorectal carcinoma (CRC) 13, [17] [18] [19] [20] and leukemia. 21 Inhibition of NANOG expression has led to a reduction in tumorigenicity and such in vitro characteristics of stem cells as anchorage-independent growth, 13, 19 whereas overexpression may increase tumorigenicity. 14 The role of NANOGP8 as a potential substitute for NANOG when NANOG is absent is not entirely clear. Jeter et al. 13 demonstrated that overexpression of NANOGP8 in cells transfected with a Lentiviral vector encoding shRNA targeting NANOG's 3'UTR (untranslated region) 'rescued' proliferation but not in cells transfected with short hairpin RNA (shRNA) targeting the coding sequence of NANOG. Thus, the role of NANOGP8 in maintaining the stemness of malignant cells needs further definition.
Our purpose in this study was to define whether NANOGP8 could replace NANOG in CRC in mediating stem cell like characteristics. We assessed this by assessing the ability of NANOGP8 to 'rescue' spherogenicity in individual CRC cells whose NANOG expression had been inhibited. During this study, we confirmed and extended the observations of others 13, [17] [18] [19] [20] that both NANOG and NANOGP8 are expressed in clinical metastases of CRC, that inhibition of NANOG reduces the expression and activity of several regulators of G2 cell-cycle progression and that inhibition of NANOGP8 decreases the stem-like activities of CRC both in vitro and in vivo. Finally, we show that the capacity of individual CRC cells to form spheroids in suspension culture in serum-free medium can be maintained by NANOGP8 in the absence of NANOG.
RESULTS
The retrogene NANOGP8 is upregulated in clinical samples NANOG and its retrogene NANOGP8 12, 13, 16 are frequently upregulated in human cancers. To investigate if NANOG is expressed in CRC, we first did an immunofluorescent assay (IFA) on 10 clinical liver metastases with a commercially available NANOG antibody, which recognizes both NANOG and NANOGP8. NANOG was mainly located in cytoplasm in CRC (Figure 1a ) as described by Meng et al. 18 This is in contrast to the control specimen of a human seminoma-a germ cell tumor-that has the expected intranuclear location for NANOG (Figure 1b) . CD44v6 was used to mark CRC cells because its expression reflects propensity for metastasis in CRC patients. 22 When the antibody to NANOG was blocked with recombinant NANOG peptides, the fluorescence due to NANOG was removed ( Supplementary Figures 1a-e) . The IFA staining is specific to NANOG and 8 of 10 liver metastases express NANOG proteins (Supplementary Table 1) .
In order to further distinguish which NANOG is expressed in clinical samples, we examined the transcripts for those genes. Since NANOGP8 is an intronless retrogene located on chromosome 15 whereas the NANOG gene is located on chromosome 12 23 and differs by six nucleotides with one 12 or two to three nonsynonymous amino-acid changes due to other nonconserved nucleotide changes, 13, 16, 24 we found a single restriction endonuclease that distinguishes the two genes: AlwNI, 25 an enzyme that identifies a palindromic hexanucleotide sequence in NANOGP8 but not in NANOG at position 144 relative to the translational start site (Figure 1c) . NANOG transcripts were identified in 8 of 10 liver metastases and also in 4 adjacent microscopically normal liver sections (Figures 1d-f) . Moreover, six of the eight positive tumor specimens contained NANOGP8 transcripts with two each containing only NANOGP8 or NANOG transcripts. Only one of the adjacent liver specimens contained NANOGP8 while the three others only expressed NANOG transcripts (Figures 1d-f) . Sanger sequencing confirmed the endonuclease results (data not shown). Thus, based on this small sample B80% of clinical CRC metastases expressed NANOG family members with 75% of those expressing NANOGP8.
The retrogene NANOGP8 is the prevalent NANOG expressed in CRC Expression of NANOGP8 in clinical tissues is important but is it translated and functional in CRC? To assess this, we investigated whether ES TFs and other CSC-related markers are upregulated in six CRC lines during formation of spheroids in serum-free medium. Relative expression of NANOG transcripts was consistently increased in spheroids 8-to 122-fold compared with monolayer cultures except in KM12c whereas the relative expression of OCT4 was B40-fold. The SOX2 expression varied between 1-and 63-fold in spheroids compared with monolayer cultures (Figures 2a and In all, 5 m formalin-fixed paraffin-embedded specimens of liver metastases sections were analyzed for the expression of NANOG protein and CD44v6 by IFA that included DAPI nuclear counter stains. Patient 9 (whose tumor expressed only NANOGP8 transcripts) (a) is shown. Positive controls included similar sections of formalin-fixed paraffinembedded human seminoma that is known to express nuclear NANOG (b). Images were captured on a Nikon 90i microscope with a DU888 EMCCD camera and analyzed with NIS-Elements software (Nikon Instuments, Inc., Melville, NY, USA). Object magnification, Â 20. White bars are 10 mm. (c) The restriction endonuclease that distinguishes the two genes is AlwNI, an enzyme that identifies a palindromic hexanucleotide sequence in NANOGP8 but not NANOG at position 144 relative to the translational start site. (d-f ) Sections from liver metastases that had been resected were microdissected and total RNA prepared from tumor and adjacent normal liver. RT-PCR products were run out on agarose gels and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control and eight metastatic tumors (T) and four adjacent microscopically normal liver samples (N) contained NANOG transcripts (d). When the positive cDNAs from (d) were subjected to digestion with AlwNI, six tumor samples and one adjacent liver contained NANOGP8 (e, f ). These results were confirmed by direct sequencing (data not shown). The relative NANOGP8 expression is calculated as the ratio between densitometry reading of NANOGP8 and total NANOG by using Image J software (National institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/index.html). bp, base pair; D, digested with AlwNI; M, 100 bp DNA ladder marker; N, adjacent normal liver sample; Ng, NANOG; NP8, NANOGP8; À , negative; þ , positive; T, tumor sample; UD, undigested. b). However, the expression of CD44, CD133 or CD166 was not significantly increased in spheroid cultures compared with monolayer except in KM12c, CX-1 and LS 174T ( Supplementary  Figures 2a and b) . When cDNA from the CRC lines was digested with AlwNI, NANOGP8 was expressed in both the monolayer (Figure 2c ) and spheroid cultures (Figure 2d ) of the six CRC lines. Over 84% of the NANOG expressed in monolayer cultures of CX-1 and Clone A was NANOGP8 and this expression increased to over 94% in spheroids (Figure 2e) . The results were confirmed by direct sequencing (data not shown). Thus, expression of NANOG transcripts is increased as CRC transition to vertical growth to form spheroids, NANOGP8 is the prevalent form of NANOG expressed in CRC cell lines and was the most consistently upregulated TF in this panel of six CRC lines compared with OCT4 and SOX2.
To confirm that NANOGP8 is translated in CRC, we used tandem mass spectrometry (MS/MS) to identify the NANOGP8 protein in CRC lines. Extracts from Clone A overexpressing NANOGP8 were immunoprecipitated, isolated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), subjected to in gel tryptic digestion followed by MS/MS. Four NANOGrelated peptides (KTWFQNQRM, KYLSLQQMQELSNILNLSYKQ, KKEDKVPVKK and KGKQPTSAENSVAKK) were identified in extracts from Clone A overexpressing NANOGP8. Interestingly, the last peptide is unique to NANOGP8, with the shift from Lys (K) in NANOG to Asn (N) in NANOGP8 at codon 82 ( Figure 2f ; Supplementary Figure 3a) . This amino-acid change was also reported 16, 24 and confirmed by gene sequencing. NANOG/ NANOGP8 proteins were not identified in extracts of CRC cell lines without overexpression by transduction presumably because CRC cell lines express low levels of endogenous proteins.
Modulation of NANOG gene expression affects spherogenicity of individual CRC cells The capacity of single CRC cells to form spheres-a hallmark of malignant potential-was tested in six cell lines in serum-free medium in ultra-low attachment (ULLA) plates in individual wells with spheroids of 50 or more cells scored after at least 9 days of culture. All CRC lines formed spheroids at frequencies that ranged from 1 to 56% of single cells plated ( Figure 3a) .
We then inhibited total NANOG mRNA expression using lentiviral-delivered shRNA to examine the functional relevance of NANOG in spherogenicity in CRC cell lines. Transduction of Clone A and CX-1 with a commercial shNanog reduced NANOG transcript levels in Clone A and CX-1 by at least 50% (Supplementary Figures 4c and d) and NANOG protein levels by 90% (Figure 3b ). In addition, shNanog transduction decreased OCT4 transcripts significantly in both Clone A and CX-1 with trends in reduction of SOX2 transcript levels ( Supplementary Figures 4a and b) . Moreover, shNanog transductants of Clone A and CX-1 lacked expression of NANOG but did express NANOGP8, albeit at reduced levels (Figures 3e and f, respectively). When Clone A shNanog cells were secondarily transduced with NANOG or NANOGP8, the level of NANOG transcripts were a fold higher while the NANOGP8 levels The relative NANOGP8 expression is calculated as the ratio between densitometry reading of NANOGP8 and total NANOG by using Image J software. Direct sequencing confirmed that NANOGP8 is consistently upregulated in Clone A and CX-1 spheroids (e). Numbers in (e) stand for the numbers of NANOG or NANOGP8 in sequenced clones. (f ) MS/MS spectrum of a NANOGP8 tryptic peptide GKQPTSAENSVAK. This peptide is unique to NANOGP8, which includes the shift from Lys (K) in NANOG to Asn (N) in NANOGP8 at codon 82. bp, base pair; D, digested with AlwNI; M, 100 bp DNA ladder marker; UD, undigested.
were increased by nearly 30% compared with levels in shNanog Clone A (Figure 3e ). When the relative distribution of NANOG and NANOGP8 is combined with the increase in levels of transcripts in the shNanog cells overexpressing NANOG or NANOGP8, the levels of either gene were similar to those of the parental untreated Clone A or CX-1 (Figures 3c and d; Supplementary Figures 4c and  d) . Overexpression of NANOGP8 significantly increased spherogenicity in both Clone A and CX-1 shNanog cells but overexpression with NANOG only increased spherogenicity in Clone A shNanog (Figures 3c and d) . The inability of NANOG overexpression to 'rescue' spherogenicity in CX-1 may be associated with the response of the CX-1 cells to transduction with NANOG since the relative gene transcript expression is not as high as in Clone A even though the total NANOG transcript levels were higher in the overexpressing shNanog cells than in the parental untreated cells (Supplementary Figures 4c and d) . In contrast, transduction with NANOGP8 did achieve similar relative increases over the transcript levels in shNanog transductants. Thus, NANOGP8 expression appears to rescue the capacity of single CRC cells to form spheroids in the absence of parental NANOG.
Inhibition of NANOG decreases tumorigenicity and experimental metastasis by CX-1 CRC were injected subcutaneously in NOD/SCID mice in cell dilutions of 10 3 -10 5 cells per mouse. At 10 3 and 10 4 cells per mouse, CX-1 cells transduced with shNanog had fewer tumors than did either the parental cell line or the pLKO.1 control (Figure 4a ). We elected to test different constructs in NOD/SCID mice injected subcutaneously with 10 5 cells in order to assess tumorigenicity at a consistent cell concentration between experiments. The growth of shNanog transduced CX-1 was slower than the pLKO.1 control since the median number of days to palpable tumor is increased about 50% (Figure 4b ). However, overexpression of either NANOG or NANOGP8 can dramatically shorten the time to palpable tumor ( Figure 4b ). In addition, 50% of the mice in the shNanog CX-1 groups remained tumor free during the time of the experiment (Figure 4b ). Thus, inhibition of NANOG decreased the growth of CX-1 in vivo.
Another test of the effect of shRNA to NANOG on the malignant phenotype involves experimental metastasis since liver colonization after intrasplenic injection of viable CRC cells is associated with recurrence in patients operated on for cure. 26 shNanog CX-1 cells failed to form grossly visible or microscopic hepatic liver colonies compared with either the parental CX-1 cells or CX-1 cells transduced pLKO.1 (Figure 4c ).
Mechanism of action of inhibition of NANOG Transductants of CX-1 and Clone A were analyzed for the effect of NANOG inhibition or overexpression on cell proliferation. Analysis of cell proliferation indicated that shRNA of NANOG caused both CX-1 and Clone A cells to proliferate more slowly than the parental or empty vector control (Figures 5a and b) . In contrast, NANOG or NANOGP8 overexpression in Clone A or NANOG in CX-1 increased cell proliferation (Figures 5a and b) . When cell-cycle protein expression was analyzed, Wee1 expression (Figure 5c ) was decreased significantly with downregulation of phosphorylation of Cdc2, Cdc25C and other proteins involved in the G2/M aspect of the cell cycle (Figure 5c ). To further explore the potential molecular mechanisms of NANOG-promoted cell proliferation in CRC, we analyzed the interaction between NANOG and Pin1, a mitotic kinase that is phosphorylated on multiple Ser/Thr-Pro motifs 27 to maintain pluripotency and cell proliferation. 28 IFA results show both NANOG and Pin1 are perinuclear in Clone A (Figure 5d ). Reciprocal co-immunoprecipitation experiments there is a single-nucleotide alteration that identifies NANOGP8. Digestion with AlwNI reveals that shNANOG inhibits NANOG and transduction with either lentiviral vector NANOG or NANOGP8 increased NANOG or NANOGP8 trancripts, respectively. The relative NANOGP8 expression is calculated as the ratio between densitometry reading of NANOGP8 and total NANOG by using Image J software. bp, base pair; D, digested with AlwNI; M, 100 bp DNA ladder marker; UD, undigested.
confirmed that NANOG and Pin1 interact in Clone A and Clone A transduced NANOGP8 (Figure 5e ). Thus, NANOG proteins may have a cytoplasmic function as well as its function as a TF.
Inhibition of NANOGP8 decreases spherogenicity, inhibits tumorigenicity and affects side population If NANOGP8 is the prevalent form of NANOG expressed in CRC, then it would be appropriate to target NANOGP8 to spare inhibition of NANOG if it is required for normal adult stem cell function. shRNAs were designed for both NANOG and NANOGP8 based on guidelines developed for inhibition of SNPs (singlenucleotide polymorphisms). 29, 30 The designs are termed allelespecific shRNA to NANOG because, although not alleles at the same locus, the single nucleotide differences between NANOG and NANOGP8 are similar to targeting SNPs. shRNAs were designed to target the most 3' single nucleotide difference at nucleotide 759 in the coding sequence (Supplementary Figure 3b) . When tested for specificity of inhibition of NANOG versus NANOGP8, the shRNAs were tested on the human embryonal carcinoma PA-1 that only expresses NANOG, 12 which is confirmed by AlwNI cutting and direct sequencing (Supplementary Figure 5a) and the CX-1 line that expresses predominantly NANOGP8. The potential candidate should be the shRNA that inhibits NANOGP8 in CX-1 and has less effect on NANOG in PA-1. shNp8-1 did not inhibit the expression of NANOG transcripts in PA-1 whereas the shNg-1 did (Figure 6a ). In contrast, shNp8-1 inhibited the more prevalent NANOGP8 transcripts in CX-1 (Figure 6b ). When tested for their ability to inhibit single-cell spherogenicity in CRC, shNp8-1 significantly inhibited sphere formation in three cell lines (Figures 5c-e) whereas shNg-1 did not.
In addition, stem cells are frequently identified as the 'side population' (SP) based on ABCG2-mediated efflux of Hoechst dye. 31 We could not measure the SP fraction of MIP-101, Clone A 1 (h, i) ) or day 31 (Clone A (j)). Five tumors are shown from each CX-1 group (h) and tumor weights are shown in (i, j). The dotted line is a cutoff of 75 mg with both CX-1 and Clone A transduced tumors weighing o75 mg whereas the untreated CX-1 (i) or Clone A (j) were heavier. P-value by contingency table analysis with Bonferroni correction.
and LS 174T because the inhibitor did not block dye efflux even at high concentrations without toxicity to the cells (data not shown), so we did SP analysis in CX-1 and KM12c lines. The expression of ES TFs was first analyzed in CX-1, SP and non-SP by qRT-PCR (reverse transcriptase polymerase chain reaction). Relative expression of the TF transcripts were consistently increased in SP two-to threefold compared with non-SP and parental CX-1 cells (Supplementary Figure 5b) . In order to investigate whether NANOGP8 can affect the size of the SP fraction, we transduced the CX-1 and KM12c CRC lines with shNp8-1 to inhibit NANOGP8 or overexpressing NANOG or NANOGP8 and measured the SP fraction. Allele-specific inhibition of NANOGP8 reduced the size of the SP by 450% compared with the untreated parental line, while overexpression of NANOGP8 increased the SP fraction by two-to fourfold in these two CRC lines (Figures 6f and g; Supplementary  Figures 6 and 7) .
We then tested whether inhibition of NANOGP8 by shNP8-1 inhibited tumorigenicity in mice. Clone and CX-1 were transduced in vitro for 7 days and then injected into groups of 10 NOD/SCID mice at 10 5 cells per mouse mice that were killed 26 (CX-1, Figures  6h and i) or 31 (Clone A, Figure 6j ) days later, tumors harvested and weighed. CX-1 and Clone A transduced with shNp8-1 were significantly lighter than the other groups (Figures 6i and j) with 30% of CX-1 and 40% of Clone A shNp8-1 treated mice tumor free (Figures 6h-j) . Thus, inhibition of NANOGP8 inhibits tumorigenicity in CRC in both CX-1 and Clone A.
DISCUSSION
Our data support the role of NANOG in modulating stemness in human CRC as measured by single-cell spherogenicity, the fraction of the SP and growth in vivo in immunoincompetent mice. Inhibition of NANOG expression within CRC generally decreased these effects while overexpression of NANOG or NANOGP8 had the opposite outcome. These data indicated that NANOG expression can induce a stem-like state in CRC, which is consistent with the NANOG function reported in prostate cancer, 14 OCT4 in melanoma cells 32 and SOX2 in breast cancer cells. 33 It is interesting that any one of these three ES TFs is enough to induce differentiated cancer cells to a stem-like state. One possible explanation is that NANOG, OCT4 and SOX2 individually and together can initiate and support the reprogramming process by activating their embryonic transcriptional factor networks. [34] [35] [36] [37] Expression of OCT4 and SOX2 is associated with clinical outcome in various human malignancies including lung, 38 esophageal, 39, 40 ovarian, 41 cervical 42 and gastric 43 carcinomas. Expression of NANOG has been identified as a component of an ES cell signature in various human carcinomas. 16, [44] [45] [46] NANOG interacts with the Hedgehog pathway 16 and epithelialmesenchymal transition 18, 47, 48 where NANOG may play a role in maintaining pluripotency that is necessary for generating tumor heterogeneity. Thus, NANOG expression may be a critical co-factor for neoplastic progression.
NANOG is expressed in primary colon carcinomas but expression was not associated with stage of disease or survival in one study. 17 However, Meng et al. 18 reported an association between NANOG protein expression and clinical outcome in CRC. This difference may be because NANOG is expressed at low levels since a whole transcriptome analysis library contained fewer than 500 reads for NANOG-related transcripts in human CRC lines that generated 10-40 million reads (data not shown). Alternatively, NANOG-related mRNAs may also have a regulatory function as suggested by Salmena et al. 49 Interestingly, Ishiguro et al.
19
confirmed that NANOG protein levels in primary CRCs were associated with both stage of disease and overall survival. Our data also confirm and extend those of others [12] [13] [14] [15] [16] 20 that the NANOG involved in malignancy is often not the prototypic embryonic gene located on chromosome 12 identified by Chambers et al. 50 but rather NANOGP8, a retrogene located on chromosome 15 identified by Booth and Holland. 23 We found that NANOG and NanogP8 are often co-expressed in CRC cell lines and liver metastases but our data do not elucidate how NANOGP8 expression is regulated because our focus was on demonstrating that NANOGP8 expression may rescue stemness characteristics when NANOG is inhibited. Macfarlan et al. 51 have recently shown that endogenous retrovirus genes may initiate ES TF expression in ES cells while also regulating ES TF protein expression through a post-translational mechanism. Whether this mechanism causes both NANOG and NANOGP8 expression in malignant cells remains to be seen. Moreover, inhibition of NANOG gene expression is associated with inhibition of cell proliferation. Since Wee1 is an important regulator of the cell cycle and also inhibition of NANOG decreased Wee1, this may be an important aspect of how inhibition of NANOG may inhibit the malignant phenotype. We also found both NANOG and Pin1 are located in the perinuclear space in the cytoplasm where they may interact to affect cell proliferation and maintain the stemness of CRC.
In summary, the present study extends previous work in that we show NANOGP8 is translated and may substitute for NANOG to maintain the stem cell characteristics of the human CRC as measured by the in vitro correlates of spherogenicity and the size of the SP. It is not clear why the response of CX-1 cells to overexpression of NANOG is not able to 'rescue' spherogenicity or why the relative levels of NANOG transcripts are not as prevalent as in the Clone A line. However, Jeter et al.
14 observed similar variations in response to overexpression of NANOG. Further work is necessary to elucidate the difference in response and control of expression of the NANOGs.
MATERIALS AND METHODS Reagents
Unless specified, all reagents were obtained from Sigma (Sigma-Aldrich, St Louis, MO, USA).
RT-PCR, restriction endonuclease digestion and qRT-PCR
Total RNA from CRC cell lines (Clone A, CX-1, KM12c, MIP-101, LS-174T and HCC-2998) was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA from CRC clinical samples was extracted using RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Austin, TX, USA). Total RNA was treated with RNase-free DNase Set (Qiagen). The RT reaction was carried out with 2 mg total RNA in a 20-ml reaction using SuperScript III first-strand synthesis system (Invitrogen, Carlsbad, CA, USA). In all, 20 ml PCR products digested with AlwNI according to the manufacturer's protocol (New England Biolabs, Beverly, MA, USA) were analyzed by electrophoresis on a 3% (w/v) agarose gel. PCR products were sequenced after TOPO TA cloning (Life Technologies, Carlsbad, CA, USA). Real-time quantitative PCR (qRT-PCR) analysis was performed with IQ5 (Bio-Rad, Hercules, CA, USA) thermal cycler in a 96-well plate. Expression level of human glyceraldehyde 3-phosphate dehydrogenase was used as internal control. Relative gene expression levels were calculated with 2 À DDCT method.
Cell culture, cell transfection, lentivirus packaging and cell transduction
The human CRC cells were cultured in RPMI (Invitrogen) media supplemented with 10% fetal bovine serum (Invitrogen) and 2 mM L-glutamine (Invitrogen) at 37 1C, 5% CO 2 incubator. Stable transductants were created by puromycin selection for shNANOG and pLKO.1 with lentiviral particles from Sigma (shNANOG was TRCN0000004885). The other shRNA lentiviral vectors used the Clone-it enzyme-free lentivector system (System Biosciences, Mountain View, CA, USA) containing the COP-GFP (green fluorescent protein) reporter with DNA oligonucleotides from Integrated DNA Technologies (Coralville, IA, USA). Zhang et al. 12 provided the full-length NANOG plasmid DNA and full-length NANOGP8 was amplified from Clone A and confirmed by sequencing. Lentiviral particles to express full-length NANOG or NANOGP8 were ligated with the Clone-it enzyme free lentivectors with an RFP reporter (System Biosciences). The allele-specific shRNAs were shNg-1 to NANOG (target sequence 5 0 -CU NANOGP8 modulates stemness in CRC J Zhang et al Sphere culture Cells were plated in ULLA plates (Corning Incorporated, Corning, NY, USA) using serum-free medium. 53 For single-cell spherogenicity assay, cells were cultured in 96-well ULLA plates at a rate of 0.6 cell/well in serum-free medium and wells containing single cells identified within 24 h. Spheroids containing 450 cells were scored after X9 days.
Cell proliferation analysis
In all, 2 Â 10 3 (per well) CRC cells were grown in 96-well plates for 48 h and 10 ml/well cell proliferation reagent WST1 (Roche Applied Sciences, Indianapolis, IN, USA) was added and then measured the absorbance at 450 nm after 4 h.
Side population (SP) analysis SP was analyzed according to the method of Lin and Goodell.
54 SP was performed on BDLSRII flow cytometer (Becton Dickinson, San Jose, CA, USA) using Becton Dickinson FACSDiva software.
Immunoprecipitation, MS analysis and western blot
Immunoprecipitation was performed using Protein G Sepharose 4 Fast Flow (GE Healthcare, Pittsburgh, PA, USA). For MS assay, the gel band was excised from the region on SDS-PAGE corresponding to NANOG molecular weight and to the NANOG signal on western blot. MS analysis was performed as described. 55 For western blot analysis, protein (50 mg) was separated in Nu-PAGE 4-12% Bis-Tris Gel (Invitrogen) and transferred onto a polyvinylidene difluoride in Tris-Glycine Transfer Buffer (Invitrogen). The membrane was blocked with 5% milk and then incubated with antibodies against anti-phosphor-Wee1 (4910, Cell Signaling Technology, Danvers, MA, USA), anti-Wee1 (4936, Cell Signaling), anti-phosphor-Cdc2 (AF888, R&D Systems, Minneapolis, MN, USA), anti-Cdc2 (9112, Cell Signaling), antiphosphor-Chk1 (ab47318, Abcam, Cambridge, MA, USA), anti-Chk1 (ab47574, Abcam), anti-phosphor-Cdc25C (ab32051, Abcam), anti-Cdc25C (ab2359, Abcam), anti-Pin1 (3722, Cell Signaling), anti-Nanog (AF1997, R&D Systems and 4893 and 4903, Cell Signaling) and anti-b-Tubulin (T4026, Sigma-Aldrich) and subsequently washed and incubated with a specific secondary antibody (NA931V and NA934V, GE Healthcare). Protein loading was normalized against b-tubulin.
Immunofluorescence assay
De-identified formalin-fixed paraffin-embedded specimens of liver metastases from colon carcinoma were obtained from the Pathology Service of the Center for Cancer Research under exemption #5426 from the NIH Office of Human Subjects. Sections 5 m thick were microdissected and RNA extracted for RT-PCR and analyzed for the presence of NANOGP8 transcripts as described above. In addition, companion 5 m sections were analyzed for the expression of NANOG (AF1997, R&D Systems) and CD44v6 (BBA13, R&D Systems) by immunofluorescence assay at 1 : 100 dilutions with DAPI nuclear counter stains. Positive controls included similar sections of formalin-fixed paraffin-embedded human seminoma. Staining was performed as described. 
